Dr. Xingsheng Hu 胡兴胜
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical and comprehensive treatment of lung cancer, breast cancer, gastric cancer, colorectal cancer, and bone metastases, with a focus on chemotherapy and targeted therapy for lung cancer.
Dr. Hu is a Chief Physician in the Department of Medical Oncology at the Cancer Hospital, Chinese Academy of Medical Sciences. Dr. Hu has long been engaged in clinical practice and teaching in medical oncology.
Name order: in Chinese the family name comes first (Hu Xingsheng). Papers usually list the name as Xingsheng Hu or Hu X.
Selected publications
82 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2025 (senior author): Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer. PubMed 40950866
- Thorac Cancer, 2025 (senior author): Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. PubMed 40785621
- Front Med, 2025 (senior author): Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting. PubMed 40616753
- J Transl Med, 2024 (senior author): Proteomic profiling reveals the significance of lipid metabolism in small cell lung cancer recurrence and metastasis. PubMed 39707352
- Chin Med J (Engl), 2024 (senior author): Prognostic significance and underlying mechanisms of STING in lung adenocarcinoma. PubMed 39245640
- BMC Med, 2023 (first author): Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies. PubMed 37118803
- BMC Cancer, 2023 (first author): Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. PubMed 37041472
- Cancer Res Treat, 2022 (senior author): The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer. PubMed 34645133
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion